We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sharing Review Data Is New ‘Frontier’ for Transparency, Hamburg Says
Sharing Review Data Is New ‘Frontier’ for Transparency, Hamburg Says
May 23, 2012
Drugmakers and the rest of the scientific community can and should benefit from the careful disclosure of FDA review data, including clinical trial reports that industry and the agency now keep closely guarded, FDA Commissioner Margaret Hamburg says.